Immunofluorescence Assay Market Size, Share, Growth, Trends, and Global Industry Analysis: By Products (Antibodies, Reagents, Kits, Instruments, Consumables and Accessories), By Type (Indirect Immunofluorescence, Direct Immunofluorescence), By Disease (Cancer, Infectious Diseases, Cardiovascular Diseases, Autoimmune Diseases, Other Diseases), By End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Hospitals & Diagnostic Centers) and Region  

Immunofluorescence Assay Market size was valued at US$ 2,786.4 million in 2023 and is poised to grow at a 6.5% CAGR from 2024 to 2030. Immunofluorescence assay is a technique combined with antigen-antibody reaction. The antibodies used in the assay are tagged or labeled with a fluorescence dye and permitted to bind with its complementary antigen. The antigen-antibody complex is further visualized in a fluorescent microscope, flow cytometer, automated imaging instrument, or array scanner. This method studies specific proteins in the cell culture, the patient's body fluid sample, and others.

The increase in the incidence of chronic disease is primarily driving the growth. Furthermore, biological studies in research and development for detecting biomolecules like proteins, glycans, and small biological and non-biological molecules of several diseases further push the market growth of immunofluorescence assays. It is also used for rapid and sensitive diagnostics of numerous chronic diseases like cancer, autoimmune diseases, infectious diseases like HIV, and neurological diseases such as Alzheimer's and Parkinson's disease. According to the National Institutes of Health (2012), autoimmune diseases are most prevalent among other diseases, and 23.5 million people in America suffer from autoimmune diseases, whereas 9 million people have cancer.

Moreover, according to Alzheimer's Association in 2018, 5.7 million Americans were affected by Alzheimer's disease.  Thus, these high incidences of autoimmune and neurological diseases and increasing government funding support to increase the revenue of the market. Apart from this, increasing demand for rapid and precise measurement of biomolecules increased the usage of immunofluorescence assay for diagnostic and research purposes, increased R&D activities, and technologically advanced techniques further propelled the market growth.

However, the high cost of diagnostic kits, chances of cross contaminations, lack of skilled labor, and weak detection signals are expected to constrain the market growth over the forecast period. Emerging economies such as China and India are witnessed to offer potential growth opportunities to key players in the coming next few years attributing to the diversified healthcare sectors in these countries and increasing research and development activities in medical and healthcare infrastructure.

Key Developments

• In April 2021, EUROPattern Microscope Live (EPML) compact immunofluorescence microscope which is combined with EUROLabOffice 4.0 (ELO 4.0) software for modern diagnostics has been launched by Euroimmun which is an international provider of medical laboratory products.
• In July 2020, a new Life Sciences Laboratory has been built by Merck KGaA which is a multinational science and technology company in Buchs, Switzerland. The Life Sciences Laboratory will accelerate and provide funding for research and development, quality control, and analytical production.